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Abstract
Aims—Given the high prevalence of psychotropic medication use in people with dementia and 
the potential for different prescribing practices in men and women, our study aimed to investigate 
sex differences in psychotropic medication use in older adults with Alzheimer's disease (AD) 
living in the US and Finland.
Methods—We used data collected between 2005 and 2011 as part of the National Alzheimer's 
Coordinating Center (NACC) in the US, and Medication use and Alzheimer's disease (MEDALZ) 
Correspondence to: Daniela C. Moga.
Author contributions: DM: study concept and design, acquisition of data, data analysis and interpretation, and preparation and 
editing of manuscript. HT: study concept and design, acquisition of data, data analysis and interpretation, and preparation and editing 
of manuscript. AMT: acquisition of data and interpretation, critical revising of the manuscript for important intellectual content, and 
final approval of the version to be published. AT: acquisition of data and interpretation, critical revising of the manuscript for 
important intellectual content, and final approval of the version to be published. JT: acquisition of data and interpretation, critical 
revising of the manuscript for important intellectual content, and final approval of the version to be published. SH: study concept and 
design, acquisition of data, data analysis and interpretation, and preparation and editing of manuscript. QW: data analysis, critical 
revising of the manuscript for important intellectual content, and final approval of the version to be published. GJ: study concept and 
design, interpretation of study findings, critical revising of the manuscript for important intellectual content, and final approval of the 
version to be published. DG: study concept and design, interpretation of findings, and preparation and editing of manuscript.
Conflict of interest: DM, AMT, QW, GJ and DG declare no conflicts of interest.
Compliance with Ethical Standards: Ethical approval: Cohort data use was approved by local ethics committees at each institution 
and owing to the de-identified nature of the data included in our current study, informed consent was waived. Specifically, for the US 
data, the Alzheimer's Disease Research Center Clinical/Research Core protocol was approved by the Institutional Review Board of the 
University of Kentucky. Ethics committee approval was not required for the MEDALZ cohort according to Finnish legislation as only 
register-based data were used and persons were not contacted.
Sponsor's role: None.
HHS Public Access
Author manuscript
Drugs Aging. Author manuscript; available in PMC 2018 January 01.
Published in final edited form as:
Drugs Aging. 2017 January ; 34(1): 55–65. doi:10.1007/s40266-016-0419-5.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
cohorts in Finland. We evaluated psychotropic medication use (antidepressant, antipsychotic, 
anxiolytic, sedative, or hypnotic) in participants aged 65 years or older. We employed 
multivariable logistic regression adjusted for demographics, co-morbidities, and other medications 
to estimate the magnitude of the association (adjusted odds ratio [aOR] with 95% confidence 
intervals [CIs]) according to sex.
Results—We included 1099 NACC participants (502 [45.68%] men, 597 [54.32%] women), and 
67,049 participants from the MEDALZ cohort (22,961 [34.24%] men, 44,088 [65.75%] women). 
Women were more likely than men to use psychotropic medications: US, 46.2% vs. 33.1%, p < 
0.001; Finland, 45.3% vs. 36.1%, p < 0.001; aOR was 2.06 (95% CI 1.58–2.70) in the US cohort 
and 1.38 (95% CI 1.33–1.43) in the Finnish cohort. Similarly, of the different psychotropic 
medications, women were more likely to use antidepressants (aOR-US: 2.16 [1.44–3.25], Finland: 
1.52 [1.45–1.58]) and anxiolytics (aOR-US: 2.16 [1.83–3.96], Finland: 1.17 [1.13-1.23]) than 
men.
Conclusionl—Older women with AD are more likely to use psychotropic medications than older 
men, regardless of study population and country. Approaches to mitigate psychotropic medication 
use need to consider different prescribing habits observed in older women vs. men with AD.
1 Introduction
Current evidence suggests a high prevalence of psychotropic medication use among people 
with dementia. In a study of older people with dementia in the US, 57% used one or more 
psychotropic medications consistently over a 1-year period, regardless of whether they were 
living in the community or nursing homes (NH) [1]. Other studies have reported a similar 
prevalence, with 51% of community-dwelling older people with Alzheimer's disease (AD) in 
Finland being exposed to anticholinergic and sedative medications (mostly psychotropic 
medications) [2]. Alarmingly, psychotropic polypharmacy is highly prevalent in older people 
with dementia, with a recent study reporting an increase from 42% in 2004 to 50% in 2013 
in patients being dispensed two or more psychotropic medications [3]. The observed high 
prevalence of psychotropic medications is of concern given the potential for significant harm 
and the limited evidence on efficacy in older people with dementia [4, 5]. Data from meta-
analyses suggest that antipsychotic use in older people with dementia is associated with 
greater mortality [6], and evidence from well-designed observational studies suggests an 
association with a range of dose-dependent adverse events, including impaired physical 
function, frailty, increased risk of hospitalization, and mortality [2, 7, 8].
Factors contributing to psychotropic medication use and subsequent poor clinical outcomes 
in older people with dementia are complex. In particular, there are limited data on the role of 
biological sex in determining psychotropic medication utilization patterns in older people 
with cognitive impairment. However, sex is an important factor to consider in clinical 
practice as it can influence healthcare, the choice of pharmacological treatments, and patient 
outcomes [9, 10]. Disability and morbidity are more prevalent in older women than men; 
therefore, this may explain why older women are more likely to use more medications 
overall [11]. For instance, one study found that potentially inappropriate medication use was 
more common in women (24.6%) than in men (19.3%) [12]. Moreover, older women were at 
50% higher odds of receiving three or more psychotropic medications than men (adjusted 
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odds ratio 1.50; 95% confidence interval [CI] 1.47–1.53). Current evidence suggests that 
women with dementia are more likely to use certain psychotropic medications such as 
antipsychotics than men [13]. There are also differences in behavioral and psychological 
symptoms of dementia with men being more physically aggressive, apathetic, and 
regressive, while women tend to display depression, anxiety, and agitation more frequently 
[14, 15]. This may result in sex differences in medication utilization patterns, with men 
being more likely to use antipsychotics or a high dose [16]. Older men with dementia are 
more likely to experience adverse events when given antipsychotics than older women [15, 
17].
To date, no study has explicitly compared the role of sex on psychotropic prescribing 
practices in older people with AD living in different countries. Our focus on comparing sex 
differences in psychotropic medication prescribing between countries was driven by the 
need to document patterns across populations with different healthcare systems, and 
potentially identifying country-specific factors for psychotropic medication use that could 
help guide targeted intervention to optimize medication use in this population [18]. 
Therefore, the aim of this study was to evaluate sex differences in psychotropic medication 
prescribing (referred to as ‘use’ or ‘utilization’ hereafter) in older adults with AD living in 
the US and Finland. We also aimed to examine sociodemographic and clinical 
characteristics that contribute to these differences.
2 Methods
2.1 Study Design and Population
Our investigation was conducted using data from two cohorts: the National Alzheimer's 
Coordinating Center (NACC) in the US and the Medication use and Alzheimer's disease 
(MEDALZ) in Finland. Cohort data use was approved by local ethics committees at each 
institution and owing to the de-identified nature of the data included in our current study, 
informed consent was waived. Specifically, for the US data, the Alzheimer's Disease 
Research Center Clinical/Research Core protocol was approved by the Institutional Review 
Board of the University of Kentucky. Ethics committee approval was not required for the 
MEDALZ cohort according to Finnish legislation as only register-based data were used and 
persons were not contacted.
2.1.1 US Cohort—The NACC was established in 1999 through the funding of Alzheimer's 
Disease Centers (ADC) by the National Institute on Aging. Since inception of the Uniform 
Data Set in 2005, 34 past and present ADC throughout the US collected self-reported 
information and conducted standardized cognitive and behavioral assessments in participants 
with the full range of cognitive functioning, from normal to dementia. Participants are 
recruited through clinician or self-referral (patients or family members), or through active 
community recruitment strategies following ADC-specific recruitment protocols. Detailed 
descriptions of the cohort as well as the various instruments and assessments used for data 
collection are described elsewhere [19–22]. Briefly, NACC UDS data includes information 
on sociodemographic characteristics, family history, medical history, and medication use. In 
addition, participants undergo neuropsychological evaluations using validated instruments.
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For this investigation, we used UDS enrollment and yearly follow-up visits data collected 
between 2005 and 2011 to reflect the similar time window available from the Finnish cohort. 
We identified 1169 participants newly diagnosed with AD during the cohort follow-up (i.e., 
free of dementia at enrollment), of which 1099 were aged ≥65 years. A participant was 
considered to have AD if they met the criteria for dementia and had probable AD as the 
primary clinical diagnosis based on the National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders 
Association (NINCDS/ADRDA) criteria [23]. Subjects without dementia diagnosis or those 
with non-AD dementia were excluded from this analysis.
2.1.2 Finnish Cohort—The MEDALZ cohort is a population-based register of all 
community-dwelling individuals diagnosed with AD between 2005 and 2011 in Finland. 
The MEDALZ cohort collected information from several nationwide registers including the 
Prescription Register (1995–2012), Special Reimbursement Register (1972–2012), Hospital 
Discharge Register (1972–2012), and Statistics Finland (socioeconomic data since 1970 and 
causes of death 2005–12). The Prescription Register includes information on reimbursed 
purchases of medications classified according to the Anatomical Therapeutic Chemical 
classification system [24]. The register includes data on community-dwelling individuals 
(i.e., medications used in hospital or NH are not recorded). Older adults with AD have been 
identified from the Special Reimbursement Register [16, 25–28].
From this Finnish cohort, of the 70,718 adults diagnosed with AD between 2005 and 2011, 
our study included 67,049 individuals aged ≥65 years who were alive at the time when 
medication utilization was assessed (i.e., 6 months after the diagnosis). Similarly to the US 
cohort, the AD diagnosis was based on the NINCDS/ADRDA and Diagnostic and Statistical 
Manual of Mental Disorders, 4th edition criteria [23, 29]. In Finland, current guidelines for 
care recommend that all persons with clinically verified AD should be prescribed anti-
dementia drugs unless there are contraindications for use [30].
2.2 Study Variables
The index date was defined as the first visit when the patient was identified with AD during 
the cohort follow-up (US cohort) or 6 months after the date of diagnosis (Finnish cohort). 
Medication exposure in the US cohort was measured from self-reported data using the 
‘brown bag’ medication review approach (i.e., the participant or a family member were 
asked to bring all the medications to the research assessment) on prescription and over-the-
counter medications for the 2-week window preceding the index date [21]. Medication 
exposure in the MEDALZ data was defined as medications used during a 2-week period 
before the index date from register-based data. The use periods were modeled with the 
PRE2DUP method as previously described [31–33]. Exposure to psychotropic medication 
was defined as the use of an antidepressant, antipsychotic, or an anxiolytic, sedative, or 
hypnotic. We also assessed the use of medications approved for AD treatment and the total 
number of medications used at the index date for each person in the two cohorts.
Sociodemographic characteristics included race, education, living situation, and type of 
residence for the US cohort and socioeconomic position for the Finnish cohort. Race was 
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categorized as White, Black, or other. Education was categorized as high-school degree or 
less, college education, or graduate education. Living situation was defined as living alone, 
living with spouse or partner, or other living arrangements. Residence type was described as 
single family residence, retirement community, assisted living (assisted living, boarding 
home, adult family home, and skilled nursing facility, or NH), or other. Occupational 
socioeconomic position was defined for those included in the Finnish cohort as the highest 
recorded position since 1972 and was obtained from the censuses maintained by Statistics 
Finland. A six-category variable was constructed with the following categories “managerial/
professional”, “office worker”, “farming/forestry”, “sales/industry/cleaning”, “unknown”, 
and “did not respond” [34, 35].
Cognitive evaluation information was available only from the US data and included the 
clinical dementia rating (CDR) [36], and the Mini-Mental State Examination (MMSE) [37]. 
In our study, we included the standard global CDR score categorized as no impairment 
(CDR = 0), questionable impairment (CDR = 0.5), mild impairment (CDR = 1), and 
moderate tosevere impairment (CDR = 2 or 3). MMSE score was categorized as normal 
(MMSE = 27–30), mild impairment (MMSE = 21–26), moderate impairment (MMSE = 11–
20),or severe impairment (MMSE = 0–10).
Behavioral symptoms available only from the US data included information collected as part 
of the Neuropsychiatric Inventory Questionnaire [38, 39]; specifically, for our study, the 
analyses included indicators for the presence of symptoms of delusions, hallucinations, 
agitation or aggression, depression or dysphoria, and anxiety.
Co-morbidities were measured at the index date for both cohorts. For the US cohort, 
indicators were created based on the health history at the index date visit. For the Finnish 
cohort, the Special Reimbursement Register data were used for defining co-morbidities. 
Some co-morbidities were available for both cohorts (cardiovascular diseases, diabetes 
mellitus, stroke, history of seizures [US cohort] or epilepsy [Finnish cohort]), but some of 
them were only available for the US cohort (obesity, depression in the previous 2 years and 
Geriatric Depression Scale [40], psychiatric diagnosis, urinary incontinence) or for the 
Finnish cohort (history of hospital-treated depression, rheumatoid arthritis, asthma/chronic 
obstructive pulmonary disease, history of hip fracture). Cardiovascular diseases indicators 
included chronic heart failure, arterial hypertension, coronary artery disease, and chronic 
arrhythmia. History of stroke and hip fracture were collected from the Hospital Discharge 
Register for the Finnish cohort. Genetic information (apolipoprotein E allele) was available 
for US cohort participants.
2.3 Statistical Analyses
Baseline characteristics were compared using descriptive statistics (mean, standard deviation 
[SD], and range for continuous variables, and proportions for categorical variables). We used 
the t test (or the Mann–Whitney test if normality assumptions were not met) to determine 
statistical association with continuous variables, and the chi-square statistic to document the 
statistical association with categorical variables. Prevalence of psychotropic medication use 
by sex, overall, and for each of the different medication classes included in this category was 
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evaluated for both cohorts. We also investigated whether age (<8 0 and ≥80 years), in 
addition to sex, influenced our results.
We used unconditional logistic regression to estimate the association between sex and 
psychotropic medication use. Two different multivariable models were developed for each 
cohort to address confounding and to determine the adjusted estimates for odds ratio (aOR) 
and the 95% CI. The first model included baseline characteristics available from both 
countries (Table 1). The second model added country-specific information to those included 
in the first model (Table 1 plus country-specific information from Table 2). All analyses 
were conducted at the level of statistical significance of 0.05 using SAS version 9.4 (SAS 
Institute Inc., Cary, NC, USA) [41].
3 Results
The US cohort included 502 (45.68%) men and 597 (54.32%) women with AD, whereas the 
Finnish cohort included 22,961 (34.24%) men and 44,088 (65.75%) women with AD. Table 
1 shows the distribution of baseline characteristics by sex for the information available from 
both cohorts. Additional country-specific baseline characteristics are included in Table 2. 
Mean (SD) age for participants at the index date was 80.2 (7.43) for the US cohort and 80.6 
(6.1) for the Finnish cohort. Men had a statistically significantly higher prevalence of 
cardiovascular disease and diabetes (both countries), as well as stroke and epilepsy 
(Finland); there were no sex differences for stroke and seizure history for US cohort 
participants. When comparing the number of medications used, in the US, the prevalence of 
using five or more medications was higher in men than in women (Table 1). In addition, men 
in the US cohort were more likely to report the use of cognitive enhancers than women 
(Table 1). When comparing psychotropic medication use by sex, women were more likely to 
use psychotropic medications than men in both the US (46.2% [95% CI 42.2–50.3] vs. 
33.1% [95% CI 28.9–37.4], p < 0.001) and Finland (45.3% [95% CI 44.8–45.8] vs. 36.1% 
[95% CI 35.5–36.7], p < 0.001) (Table 1; Fig. 1). In relation to medication classes, the sex 
difference was observed in both countries for antidepressants and anxiolytics, while sex was 
associated with antipsychotic use in Finland only. When evaluating sex differences by age, 
the pattern of use when comparing men and women remained the same for the two age 
groups investigated (Fig. 2).
Of the behavioral symptoms evaluated from the NACC cohort, depression/ dysphoria was 
most commonly reported by women (Table 2). No sex differences were observed between 
men and women concerning other behavioral symptoms.
The results of the logistic regression analysis are presented in Table 3. Specifically, when 
comparing women with men in the US cohort, the unadjusted odds ratio was 1.74 (95% CI 
1.36–2.23), while the aOR was 2.08 (95% CI 1.59–2.71) in the limited data model, and 2.29 
(95% CI 1.56–3.37) in the extended data model. The estimates from the Finnish data were 
odds ratio = 1.47 (95% CI 1.42–1.52) in the unadjusted analysis and odds ratio = 1.39 (95% 
CI 1.34–1.44) and odds ratio = 1.38 (95% CI 1.33–1.43) for the limited data model and the 
extended data model, respectively. Similarly, in both countries, women were more likely to 
use antidepressants or anxiolytics as compared with men, in both unadjusted and adjusted 
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analyses. However, when looking at antipsychotic use, there was not a statistically 
significant difference between women and men in the US cohort (Table 3). However, women 
were more likely than men to report using antipsychotics in the Finnish cohort (Table 3).
4 Discussion
To our knowledge, this is the first study to explicitly investigate psychotropic medication use 
according to sex in older adults with AD. We found that psychotropic medication use was 
more common among older women than older men with AD in both the US (46 vs. 33%) 
and Finland (45 vs. 36%). After adjusting for covariates, older women with AD were two 
times more likely to receive psychotropic medications in the US cohort (aOR = 2.06; 95% 
CI 1.58–2.70) and 1.4 times more likely (aOR = 1.38; 95% CI 1.33–1.43) in the Finnish 
cohort, compared with older men. Despite differences in medication data collection 
approaches across study cohorts (i.e., self-reported in the US vs. prescription registry data in 
Finland), it is important to note that sex differences were apparent in both cohorts. Self-
reported data are subject to bias and may have resulted in underreporting. However, 
considering that the medication inventory in the US cohort was conducted using the brown-
bag approach, the potential misclassification of medication use by sex is likely non-
differential and thus probably underestimating the real sex difference. Although it was not 
the primary focus of our article, it is worth noting that, in the US cohort, polypharmacy (five 
or more medications) was more common among men than women, and men were more 
likely to use cognitive enhancers than women. The reason for sex differences in cognitive 
enhancers use should be further investigated in future studies.
The findings of our study are similar to recent studies comparing the use of cognitive 
enhancers and psychotropic medications in women and men [1, 13, 42]. In a study 
evaluating the prevalence of psychotropic medications use across different settings by 
Medicare beneficiaries in the US, sex was an important factor associated with use [1]. 
Similarly, in a European study, women with dementia were more likely to use antipsychotics 
than men [13]. A study using the National Health and Nutrition Examination Survey in the 
US found that for all race categories, older women were more likely to report psychotropic 
medication use than men [42]. In a recent study of community-dwelling older adults living 
in Canada, older women were at 16% higher odds of receiving potentially inappropriate 
medications, measured using 2015 Beers Criteria than older men [43]. These differences 
were mostly the result of older women using psychotropic medications including 
antidepressants and benzodiazepines. Older women are more likely like to have more co-
morbidities than men; therefore, this may in part explain differences in psychotropic 
medication use. Moreover, the importance of considering personality traits as a potential 
factor influencing psychotropic medication use has been also highlighted [44]. Future 
studies investigating the role of sex in psychotropic prescribing patterns should account for 
personality traits.
In our study, in the US cohort, psychotropic medication use consisted mainly of 
antidepressant use, whereas antipsychotics and anxiolytics were less commonly used among 
both men and women. In Finland, anxiolytics were the most frequently used psychotropic 
medication among men, while antidepressants and anxiolytics were the most commonly 
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used classes among women (Fig. 1). The prevalence of behavioral symptoms might explain 
the observed difference between men and women. Previous studies have reported that 
women experience behavioral symptoms, especially depressive symptoms, more frequently 
than men [14, 45, 46]. We compared the prevalence of behavioral symptoms in the US 
cohort and only depression and dysphoria were more frequently reported by women. We 
also adjusted our regression model for behavioral symptoms in the US cohort and the 
association between female sex and psychotropic medication use persisted. Antipsychotic 
use was significantly more frequent in the Finnish cohort than in the US cohort. This 
discrepancy might be related to AD disease severity or may reflect national treatment 
practices and restricted use of antipsychotics in the US. Previous research evaluating 
antipsychotic use in US veterans with dementia living in the community showed that 14–
15% of veterans had outpatient prescriptions for an antipsychotic [47]. In our US cohort, 
95% of the participants had questionable or mild impairment (CDR global = 0.5 or 1), and a 
small proportion had behavioral symptoms, which can explain the low prevalence of 
antipsychotics. Furthermore, when looking at use by level of impairment, prevalence 
increased from 1.17% for a CDR global score of 0.5–3.6% for CDR of 1, and to 34.62% for 
a CDR of 2 or 3. In Finland, clinical care guidelines recommend antipsychotics and 
anxiolytics only for short-term use and if non-pharmacological options are not effective [30]. 
However for the Finnish cohort, we did not have information on disease severity at the time 
we measured antipsychotic use and we could not evaluate if the same pattern would be 
identified in the US cohort. Both cohorts included persons newly diagnosed with AD, and 
the mean age was similar.
Importantly, there is a need for more research to elucidate the role of sex and its impact on 
clinical outcomes among older people with and without dementia. Recent findings on the 
association between antipsychotics and mood stabilizers and impairment on activities of 
daily living in older women suggest sex differences in response to psychotropic medication 
among older people with dementia living in NH [48]. In addition, it would be important to 
investigate whether the observed sex differences in the use of psychotropic medications are 
consistent over time.
4.1 Strengths and Limitations
4.1.1 US Cohort—An important strength of the NACC data comes from the use of 
validated instruments and standardized testing to collect patient-reported information and to 
conduct in-depth cognitive evaluations in all study participants. One of the limitations in 
using these data stems from the collection of data at enrollment and yearly after. Our 
approach of defining the index date as the date a participant was first identified with AD 
during follow-up in the cohort does not necessarily coincide with the time she/he was first 
diagnosed with AD. In addition, given that medication use asked about current medications 
taken by the participant (i.e., within 14 days of the visit), we could not ascertain 
psychotropic medication exposure (and other medications) accurately. Participants may have 
been misclassified as non-users in the situation in which they started and stopped treatment 
between two consecutive study visits. Last, considering the recruitment strategies for the 
NACC, participants enrolled in this cohort were not necessarily a representative random 
sample for the entire US population of patients with or without cognitive impairment. 
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Participants in the NACC cohort, and therefore in our study, were generally more educated, 
had higher incomes, and were more likely to receive care in academic hospitals and clinics. 
Thus, careful consideration is needed when attempting to generalize our findings to all older 
adults with AD living in the US.
4.1.2 Finnish Cohort—The MEDALZ cohort included all community-dwelling people 
with clinically verified AD diagnosis in Finland. The strengths of these nationwide data 
result from the inclusion of all socioeconomic classes and the fact that medication use is 
assessed from registers, thus limiting recall bias or under-reporting. Limitations of the 
MEDALZ data relate to limitations of registers used in data collection. Register-based data 
do not include clinical information on behavioral symptoms and other indications for 
psychotropic medication use. Furthermore, we could not assess MMSE or the severity of 
AD, although all persons had a similar time period since AD diagnosis. However, possible 
delays or sex differences in the diagnostic process could not be studied. While dispensing 
data are considered a more accurate estimate of medication exposure than other sources of 
prescribing data, they may not reflect the actual medication use.
5 Conclusion
We found that older women with AD are more likely to report psychotropic medication use 
than older men in both countries. These findings may suggest that approaches to mitigate 
psychotropic medication use among older people with dementia should consider different 
prescribing habits observed in women vs. men. Further research is needed to elucidate 
underlying risk factors for the differences in psychotropic medication use in women and men 
with AD.
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Key Points
Older women with dementia were more likely to use 
psychotropic medications than older men in the US (46 vs. 
33%) and Finland (45 vs. 36%).
The difference between women and men with regard to 
psychotropic medication use persisted even after accounting 
for behavioral symptoms and other important confounders.
Our results suggest that sex needs to be taken into 
consideration when prescribing to older people with 
dementia.
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Fig. 1. Exposure to psychotropic medications according to sex in the US and Finnish cohorts
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Fig. 2. Exposure to psychotropic medications according to sex and age in the US and Finnish 
cohorts
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Table 2
Cohort-specific characteristics at the index date
Baseline characteristicsa Male, N (%) Female, N (%)b p value
US cohort
 Race 0.032
  White 446 (88.8) 491 (82.2)
  Black 34 (6.8) 65 (10.9)
  Other 22 (4.4) 41 (6.9)
 Education <0.001
  High school or less 111 (22.21) 203 (34.0)
  College 189 (37.95) 244 (40.87)
  Graduate 202 (40.24) 150 (25.13)
 Living situation <0.001
  Lives alone 49 (9.8) 214 (35.8)
  Lives with spouse or partner 408 (81.3) 256 (42.9)
  Other living arrangements 45 (9.0) 127 (21.3)
 Type of residence 0.017
  Single family residence 439 (87.5) 485 (81.2)
  Retirement community 38 (7.6) 55 (9.2)
  Assisted livinga 19 (3.8) 47 (7.9)
  Other 6 (1.2) 10 (1.7)
 Level of independence 0.651
  Able to live independently 184 (36.7) 199 (33.3)
  Requires some assistance with complex activities 247 (49.2) 297 (49.7)
  Requires some assistance with basic activities 60 (12.0) 88 (14.7)
  Completely dependent 11 (2.2) 13 (2.2)
 BMI <0.001
  Mean (SD) 25.8 (3.63) 24.6 (4.72)
  Q1, median, Q3 23, 25, 28 21, 24, 27
 BMI categories <0.001
  Obese 64 (14.4) 68 (13.6)
 Global clinical dementia rating 0.776
  No impairment 0 (0) 0 (0)
  Questionable impairment 272 (54.2) 327 (54.8)
  Mild impairment 207 (41.2) 237 (39.7)
  Moderate/severe impairment 23 (4.6) 33 (5.5)
 MMSE category 0.232
  Normal 112 (23.0) 119 (21.3)
  Mild 277 (57.0) 348 (62.4)
  Moderate 81 (16.7) 72 (12.9)
  Severe 2 (0.4) 3 (0.5)
  Unknown 14 (2.9) 16 (2.9)
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Baseline characteristicsa Male, N (%) Female, N (%)b p value
 Behavioral symptoms
  Delusions 36 (7.4) 50 (8.6) 0.481
  Hallucinations 11 (2.3) 21 (3.6) 0.199
  Agitation or aggression 137 (28.3) 158 (27.2) 0.693
  Depression or dysphoria 157 (32.4) 231 (39.8) 0.013
  Anxiety 157 (32.4) 178 (30.7) 0.541
 Geriatric Depression Scale score categories 0.616
  0–4 405 (84.2) 455 (81.1)
  5–9 59 (12.3) 84 (15.0)
  10–15 9 (1.9) 12 (2.1)
  Unknown 8 (1.7) 10 (1.8)
 Co-morbidities
  Depression within the past 2 years 178 (35.5) 279 (46.7) <0.001
  Psychiatric disorders 29 (5.8) 53 (8.9) 0.051
  Transient ischemic attack 33 (6.6) 44 (7.4) 0.606
  Incontinence: urinary 84 (16.7) 150 (25.1) <0.001
 Apolipoprotein e4 alleles 0.119
  No e4 allele 196 (39.0) 214 (35.8)
  Any copy of e4 allele 225 (44.8) 258 (43.2)
Finnish cohort
 Occupational socioeconomic position <0.001
  Office worker 714 (3.1; 2.9–3.3) 4954 (11.2; 11.0–11.5)
  Farming/forestry 5195 (22.6; 22.1–23.2) 7748 (17.6; 17.2 –17.9)
  Sales/industry/cleaning 10,528 (45.9; 45.2–46.5) 18,228 (41.3; 40.9–41.8)
  Unknown 245 (1.1; 0.9–1.2) 5318 (12.1; 11.8–12.4)
  Did not respond 159 (0.7; 0.6–0.8) 353 (0.8; 0.7–0.9)
 Co-morbidities
  Asthma/COPD 2077 (9.1; 8.7–9.4) 3908 (8.9; 8.6–9.1) 0.434
  Rheumatoid arthritis 750 (3.3; 3.0–3.5) 2319 (5.3; 5.1–5.5) <0.001
  History of hip fracture 764 (3.3; 3.1–3.6) 3351 (7.6; 7.4–7.9) <0.001
  Hospital-treated depression 519 (2.3; 2.1–2.5) 1700 (3.9; 3.7–4.1)
BMI body mass index, CI confidence interval, COPD chronic obstructive pulmonary disorder, MMSE Mini-Mental State Examination, SD 
standard deviation
aColumns display N (%), unless otherwise specified
b
For the Finnish cohort, table includes N (%) with 95% CI for %
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Table 3
Psychotropic medication use in women as compared with men
Country Unadjusted OR (95% CI) Adjusted OR (95% CI) 
Limited dataa
Adjusted OR (95% CI) 
Extended datab
Any psychotropic medication 
use
US 1.74 (1.36–2.23) 2.08 (1.59–2.71) 2.29 (1.56–3.37)
Finland 1.47 (1.42–1.52) 1.39 (1.34–1.44) 1.34 (1.29–1.39)
Antidepressant use US 1.51 (1.18–1.93) 1.76 (1.34–2.3) 2.16 (1.44–3.25)
Finland 1.58 (1.52–1.65) 1.52 (1.46–1.59) 1.48 (1.41–1.55)
Antipsychotic use US 0.85 (0.48–1.52) 0.79 (0.37–1.71) 0.61 (0.2–1.82)
Finland 1.17 (1.12–1.23) 1.09 (1.04–1.15) 1.05 (1.01–1.11)
Anxiolytic use US 1.99 (1.31–3.05) 2.43 (1.49–3.98) 2.16 (1.83–3.96)
Finland 1.31 (1.26–1.36) 1.18 (1.13–1.23) 1.14 (1.09–1.19)
CI confidence interval, OR odds ratio
a
Model adjusted for variables available for both cohorts (Table 1)
b
Model adjusted for all variables available from that cohort (Tables 1, 2)
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